Published in Circulation on May 14, 2002
Mechanisms of altered Ca²⁺ handling in heart failure. Circ Res (2013) 1.37
Pacing-induced calcineurin activation controls cardiac Ca2+ signalling and gene expression. J Physiol (2003) 1.12
Influence of promoter region variants of insulin-like growth factor pathway genes on the strength-training response of muscle phenotypes in older adults. J Appl Physiol (1985) (2007) 0.86
Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney. J Cell Mol Med (2012) 0.80
Calcineurin signaling in human cardiac hypertrophy. Circulation (2002) 0.78
Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. Br J Pharmacol (2005) 0.77
Regulation of gap junction conductance by calcineurin through Cx43 phosphorylation: implications for action potential conduction. Pflugers Arch (2016) 0.75
Regulation of sarcoplasmic reticulum Ca(2+) release by serine-threonine phosphatases in the heart. J Mol Cell Cardiol (2016) 0.75
The Cardiac Z-Disc Protein CEFIP Regulates Cardiomyocyte Hypertrophy By Modulating Calcineurin Signaling. J Biol Chem (2017) 0.75
Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med (2005) 3.59
Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart (2011) 2.87
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med (2006) 2.54
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation (2003) 2.12
Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol (2008) 2.01
RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med (2012) 1.97
Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur J Heart Fail (2011) 1.70
Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension (2007) 1.68
Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J (2011) 1.67
The estrogen receptor-alpha agonist 16alpha-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc Res (2005) 1.66
Atrial fibrillation is under-recognized in chronic heart failure: insights from a heart failure cohort treated with cardiac resynchronization therapy. Europace (2009) 1.62
Influence of arterial access site selection on outcomes in primary percutaneous coronary intervention: are the results of randomized trials achievable in clinical practice? JACC Cardiovasc Interv (2013) 1.58
The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol (2010) 1.58
Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2010) 1.58
Composite polymorphisms in the ryanodine receptor 2 gene associated with arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res (2006) 1.58
Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics (2011) 1.57
Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann Neurol (2003) 1.54
Use of the sheathless guide catheter during routine transradial percutaneous coronary intervention: a feasibility study. Catheter Cardiovasc Interv (2010) 1.53
Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. Cardiovasc Res (2010) 1.51
What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies. Heart Fail Rev (2012) 1.49
Aging reduces the efficacy of estrogen substitution to attenuate cardiac hypertrophy in female spontaneously hypertensive rats. Hypertension (2006) 1.49
Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene. Rev Port Cardiol (2005) 1.47
Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One (2009) 1.43
The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail (2010) 1.43
[Familial dilated cardiomyopathy]. Herz (2005) 1.42
Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition. J Hypertens (2002) 1.42
The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem (2006) 1.41
A comparison of drug-eluting stents versus bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis. J Interv Cardiol (2011) 1.38
Plasma membrane Ca2+ ATPase 4 is required for sperm motility and male fertility. J Biol Chem (2004) 1.37
Cytoskeleton assembly at endothelial cell-cell contacts is regulated by alphaII-spectrin-VASP complexes. J Cell Biol (2008) 1.35
A gain-of-function TBX20 mutation causes congenital atrial septal defects, patent foramen ovale and cardiac valve defects. J Med Genet (2009) 1.32
Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum Mol Genet (2006) 1.30
Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation (2007) 1.27
A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail (2009) 1.24
Mutations in GATA4, NKX2.5, CRELD1, and BMP4 are infrequently found in patients with congenital cardiac septal defects. Am J Med Genet A (2008) 1.23
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Targeted proteolysis sustains calcineurin activation. Circulation (2005) 1.21
Differential VASP phosphorylation controls remodeling of the actin cytoskeleton. J Cell Sci (2009) 1.19
Interaction of the plasma membrane Ca2+ pump 4b/CI with the Ca2+/calmodulin-dependent membrane-associated kinase CASK. J Biol Chem (2003) 1.19
Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation (2011) 1.18
Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation (2005) 1.17
Expression profiling of human idiopathic dilated cardiomyopathy. Cardiovasc Res (2003) 1.14
Local bradykinin formation is controlled by glycosaminoglycans. J Immunol (2005) 1.14
The sarcolemmal calcium pump inhibits the calcineurin/nuclear factor of activated T-cell pathway via interaction with the calcineurin A catalytic subunit. J Biol Chem (2005) 1.14
Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Eur J Hum Genet (2002) 1.13
Getting a first clue about SPRED functions. Bioessays (2007) 1.13
Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet (2008) 1.13
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood (2006) 1.12
Novel functional interaction between the plasma membrane Ca2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem (2004) 1.12
Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth. Circ Res (2009) 1.11
Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res (2007) 1.10
Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm (2009) 1.07
Targeted deletion of the extracellular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res (2010) 1.06
Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res (2007) 1.06
Usefulness of Doppler myocardial imaging for identification of mutation carriers of familial hypertrophic cardiomyopathy. Am J Cardiol (2002) 1.05
Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding. Hum Mutat (2006) 1.00
Doubly heterozygous LMNA and TTN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy. Eur J Hum Genet (2013) 1.00
Resting Pd/Pa measured with intracoronary pressure wire strongly predicts fractional flow reserve. J Invasive Cardiol (2010) 0.99
Molecular genetics of congenital atrial septal defects. Clin Res Cardiol (2009) 0.99
Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Card Fail (2010) 0.98
Conditional overexpression of neuronal nitric oxide synthase is cardioprotective in ischemia/reperfusion. Circulation (2010) 0.98
Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy. Basic Res Cardiol (2011) 0.98
Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium. J Biol Chem (2009) 0.96
Inhibition of nuclear import of calcineurin prevents myocardial hypertrophy. Circ Res (2006) 0.96
Minimising radial injury: prevention is better than cure. EuroIntervention (2014) 0.96
The heart in Anderson Fabry disease. Z Kardiol (2002) 0.95
Regulation of vascular tone in animals overexpressing the sarcolemmal calcium pump. J Biol Chem (2003) 0.95
A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy. Mol Genet Metab (2008) 0.95
Expression and subcellular localization of Spred proteins in mouse and human tissues. Histochem Cell Biol (2004) 0.94
A myomesin mutation associated with hypertrophic cardiomyopathy deteriorates dimerisation properties. Biochem Biophys Res Commun (2011) 0.94
Hypertrophic cardiomyopathy-related beta-myosin mutations cause highly variable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol (2004) 0.94
Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension (2003) 0.94
Cardiac alpha-myosin (MYH6) is the predominant sarcomeric disease gene for familial atrial septal defects. PLoS One (2011) 0.93
Plasma membrane calcium pump (PMCA4)-neuronal nitric-oxide synthase complex regulates cardiac contractility through modulation of a compartmentalized cyclic nucleotide microdomain. J Biol Chem (2011) 0.93
Tumor suppressor Ras-association domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation (2009) 0.92
What can we learn from patients with heart failure about exercise adherence? A systematic review of qualitative papers. Health Psychol (2011) 0.92
The interaction between endogenous calcineurin and the plasma membrane calcium-dependent ATPase is isoform specific in breast cancer cells. FEBS Lett (2007) 0.92
Mutations in the cardiac transcription factor GATA4 in patients with lone atrial fibrillation. Eur J Med Genet (2010) 0.91
A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail (2013) 0.91
Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail (2013) 0.91
Gene disruption of Spred-2 causes dwarfism. J Biol Chem (2005) 0.90
The VASP-Spred-Sprouty domain puzzle. J Biol Chem (2006) 0.90
AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J (2002) 0.90
Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem (2006) 0.89
Ca2+ signalling in cardiovascular disease: the role of the plasma membrane calcium pumps. Sci China Life Sci (2011) 0.89